Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 4;41(21):3724–3734. doi: 10.1200/JCO.23.00903

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Mean changes from baseline between groups during neoadjuvant treatment (1-2 weeks before surgery) and at 12 and 24 months after surgery for (A) bladder function (bladder emptying question from the International Prostate Symptom Score, administered both to males and females); (B) bowel function (Memorial Sloan Kettering Bowel Function Instrument Aggregate Global Score); (C) male sexual function (International Index of Erectile Function Total Score, administered to males only); (D) female sexual function (Female Sexual Function Index Total Score, administered to females only); and (E) overall health-related quality of life (EuroQoL EQ-5D-5L Index). Positive values represent improvement compared with baseline for all scales. Means were estimated using a general linear mixed model for each scale. Between-group differences with raw P < .05 are demarcated with ^a and P < .01 with ^b. The results for all domain subscales are shown in the Data Supplement. ^aBetween-group difference raw P < .05. ^bBetween-group difference raw P < .01 (12 months only: multiplicity-adjusted P < .05). 5FUCRT, chemoradiation with fluorouracil; FOLFOX, fluorouracil and oxaliplatin.